ArticleCancer medicine2026
Impact of Perioperative Proton Pump Inhibitors on Renal Cancer Progression. A Retrospective Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. Metastatic disease causes most deaths. We investigated the association between ATP4A gene status and survival following nephrectomy. ATP4A encodes H
methodsUsing a publicly available database, we employed in silico analysis to investigate the association between the ATP4A gene and recurrence-free survival and overall survival. After receiving institutional review board approval from the University of Texas-MD Anderson Cancer Center (#2020-0380), we conducted a retrospective analysis to investigate the association between perioperative PPIs use and progression of nonmetastatic ccRCC. We performed a propensity score analysis and utilized inverse probability of treatment weighting to balance potential discrepancies between exposure groups. A Cox proportional hazards model, weighted by inverse probability of treatment weighting, was subsequently fitted for multivariable analysis.
resultsATP4A gene expression analysis showed that high tumor levels were associated with a significant reduction in overall survival. The analysis included a total of 1775 patients with ccRCC. After propensity matching, the analysis revealed that the use of perioperative PPIs was not independently associated with a worse oncological prognosis following nephrectomies.
conclusionElevated ATP4A gene expression correlates with reduced survival, while perioperative PPI use shows no significant impact on survival outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.